Drug Trial Radar · NCT01569295
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
Last checked: Nov 19, 2026Latest source record: Mar 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Jun 15, 2012
Primary completion
Jun 10, 2019
Study completion Jun 10, 2019
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Apr 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)
Conditions
- Chronic Lymphocytic Leukemia
Interventions
IdelalisibDrug
Idelalisib 150 mg administered orally twice daily
RituximabDrug
Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions
BendamustineDrug
Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
Placebo to match idelalisibDrug
Placebo to match idelalisib administered orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to 84 months
Locations
106 sites in 18 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama
UCLA Medical Center
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
Rocky Mountain Cancer Center
Denver, Colorado
University of Florida
Gainesville, Florida
Winship Cancer Institute at Emory University
Atlanta, Georgia
Dana Farber Cancer Institute
Boston, Massachusetts
University of Nebraska Medical Center
Omaha, Nebraska
Summit Medical Group, P.A.
Morristown, New Jersey
North Shore University Hospital
Manhasset, New York
Long Island Jewish Medical Center
New Hyde Park, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Columbia University Medical Center
New York, New York
Willamette Valley Cancer Center
Eugene, Oregon
Charleston Hematology Oncology
Charleston, South Carolina
Texas Oncology
Austin, Texas
Texas Oncology PA
Dallas, Texas
Texas Oncology
Fort Worth, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Seattle Cancer Care Alliance
Seattle, Washington
Cancer Care Northwest, US Oncology
Spokane, Washington
Virginia Cancer Specialists, PC
Vancouver, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Princess Alexandra Hospital
Woolloongabba, Australia
St Vincent's Hospital - Sydney
Darlinghurst, New South Wales, Australia
Gosford Hospital
Gosford, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Monash Medical Centre - Clayton Campus
Clayton, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg
Antwerp, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Cancer Care Manitoba
Winnipeg, Manitoba, Canada
Clinical Hospital "Dubrava"
Zagreb, Croatia
Klinichki Bolnicki Centar-Zagreb
Zagreb, Croatia
University Hospital Merkur
Zagreb, Croatia
Fakultni nemocnice Brno
Brno, Czechia
Fakultní nemocnice Hradec Králové
Hradec Králové, Czechia
Fakultni nemocnice Ostrava
Ostrava, Czechia
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.